Natco Pharma
 | |
| Company type | Public |
|---|---|
| NSE: NATCOPHARM BSE: 524816 | |
| Industry | Pharmaceuticals |
| Founded | 1981 |
| Founder | VC Nannapaneni |
| Headquarters | , India |
Area served | Global |
Key people | VC Nannapaneni (Chairman and MD)[1] Rajeev Nannapaneni (CEO and Vice Chairman)[2] |
| Revenue |  ₹4,784 crore (US$570 million) (2025) |
| ₹2,550 crore (US$300 million) (2025) | |
| ₹1,883 crore (US$220 million) (2025) | |
| Website | natcopharma.co.in |
| Footnotes / references Financials as of 31 March 2025.[3] | |
Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations, active pharmaceutical ingredients and agrochemical products.[4] It is a major producer of branded oncology medicines[5] cardiology, diabetology and other pharma specialty drugs[6] at affordable prices.[7][8][9][10]
History
- Natco Pharma was founded in 1981 by V C Nannapaneni
- In 1983, operations commenced at manufacturing facility at Nagarjunasagar, Telangana
- In 1986, the company's chemical division started at Mekaguda, Telangana
- In 2008, Natco Pharma filed its first paragraph IV filing in the US with the USFDA, [11]
- In 2012, Natco Pharma obtained compulsory license to produce a cheaper and generic version of Bayer's anti-cancer medication Nexavar.[6]
- In the United States, it launched influenza medication Tamiflu with marketing partner Alvogen, multiple sclerosis treatment drug glatiramer acetate in partnership with Mylan, and hepatitis C drugs under a licensing agreement with Gilead Sciences.[11]
- In 2016, Natco Pharma launched the first Tamiflu capsule in the US market.[12]
- In 2017, Natco Pharma launched a generic version of blood cancer drug Pomalidomide in the United States.[13]
- In 2019, Natco Pharma initiated work on green-field manufacturing facilities for producing niche agrichemical products in Nellore district, Andhra Pradesh.[14]
- In 2022, its Crop Health Sciences division launched chlorantraniliprole (CTPR) based products.
- Natco launched the first generic version of Multiple myeloma drug Revlimid in the US market
References
- ^ "Facing headwinds in US, Natco Pharma looks to scale up business in China". Livemint. Retrieved 19 April 2020.
- ^ "Natco Pharma: In fine fettle". Forbes India. Retrieved 19 April 2020.
- ^ "Earnings Presentation - Q4 FY25 & FY25" (PDF). NATCO Pharma Limited. Retrieved 11 July 2025.
- ^ "Our Business | Natco Pharma". Retrieved 25 April 2022.
- ^ "Natco Pharma lines up 20 'Para IV' products". The Hindu Business Line. Retrieved 19 April 2020.
- ^ a b "How Natco defied the odds to rise up India's pharma ladder". Moneycontrol. Retrieved 19 April 2020.
- ^ PTI (17 December 2020). "Natco Pharma launches anti blood clot medication, Rivaroxaban, in India". The Economic Times. Retrieved 25 April 2022.
- ^ Akolkar, Shrikant (9 March 2017). "Natco Pharma: Top league player" (PDF). Angel One. Retrieved 25 April 2022.
- ^ "Mission & Heritage | Natco Pharma". Retrieved 25 April 2022.
- ^ Sridhar, G. Naga (25 November 2020). "Natco Pharma expects agri business to be key growth lever". www.thehindubusinessline.com. Retrieved 24 April 2022.
- ^ a b "Niche Play". Business Today. Retrieved 19 April 2020.
- ^ "Bayer cancer drug faces new Nexavar patent problems in India". www.thepharmaletter.com. Retrieved 3 February 2022.
- ^ "Natco Pharma launches blood cancer drug priced Rs 5,000–20,000, down 98% from US price". Firstpost. 10 May 2017. Retrieved 31 July 2020.
- ^ "Natco Pharma to invest Rs 100 cr for setting up agrichemical facilities in Andhra". 25 January 2019.